US 12,201,555 B2
Drug eluting ocular implant
David S. Haffner, Mission Viejo, CA (US); Kenneth M. Curry, Oceanside, CA (US); Harold A. Heitzmann, Irvine, CA (US); and David Applegate, Laguna Hills, CA (US)
Assigned to Dose Medical Corporation, Aliso Viejo, CA (US)
Filed by Dose Medical Corporation, San Clemente, CA (US)
Filed on Mar. 31, 2021, as Appl. No. 17/219,102.
Application 17/219,102 is a continuation of application No. 15/422,384, filed on Feb. 1, 2017, abandoned.
Application 15/422,384 is a continuation of application No. 13/321,144, abandoned, previously published as PCT/US2010/035319, filed on May 18, 2010.
Claims priority of provisional application 61/264,604, filed on Nov. 25, 2009.
Claims priority of provisional application 61/264,594, filed on Nov. 25, 2009.
Claims priority of provisional application 61/264,615, filed on Nov. 25, 2009.
Claims priority of provisional application 61/220,527, filed on Jun. 25, 2009.
Claims priority of provisional application 61/179,332, filed on May 18, 2009.
Prior Publication US 2021/0298948 A1, Sep. 30, 2021
Int. Cl. A61F 9/007 (2006.01); A61F 9/00 (2006.01); A61K 9/00 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 9/00781 (2013.01); A61K 9/0051 (2013.01); A61F 2210/0004 (2013.01); A61F 2250/0068 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A drug delivery ocular implant, comprising:
an outer shell shaped to define an interior space, the outer shell having a sidewall, a closed distal end, an open proximal end, and a sidewall connecting the closed distal end and the open proximal end;
a drug contained within the interior space;
a membrane proximate the open proximal end, the membrane being semi-permeable or permeable to the drug;
a cap dimensioned to fit on the open proximal end and comprising compressible regions configured to seal the cap to the outer shell; and
an anchor extending along a longitudinal axis of the drug delivery ocular implant and distally from the closed distal end, the anchor configured to affix the implant into an ocular tissue;
wherein the cap secures the membrane to the outer shell while providing at least one opening to allow the drug to elute from the implant through the membrane wherein at least a portion of the anchor is configured to extend into the ocular tissue.